Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD1 | P21728 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 10/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417487 | 0.80 | ADRB2 (0.44) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL14417498 | 0.80 | ADRB2 (0.44) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL14417636 | 0.80 | ADRB2 (0.44) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13617485 | 0.79 | ADRB2 (0.59) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13617623 | 0.77 | ADRB2 (0.78) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13617663 | 0.75 | ADRB2 (0.44) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13711797 | 0.74 | ADRB2 (0.62) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL14417635 | 0.73 | ADRB2 (0.61) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13617404 | 0.72 | ADRB2 (0.61) | ADRB2DRD3DRD2DRD1DRD4 | |
| SCHEMBL13589488 | 0.72 | ADRB2 (0.80) | ADRB2DRD3DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |